{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:02Z","timestamp":1776850442790,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>We have previously described the relationships of serum and saliva concentrations\nof caffeine, theophylline and total methylxanthines in premature infants. We have\nnow extended the previous studies in order to validate the previously derived relationships\nwith new data. The new serum to saliva relationships, derived using regression and ratio\nmodels, are cross validated against the relationships from the previous data, and vice\nversa. A good cross validation was observed for caffeine and total methylxanthine concentrations\nin infants treated with caffeine. In the theophylline treatment group, theophylline\nconcentrations did not cross validate well, whereas the total methylxanthine concentrations\ndid. Since in vivo conversion of theophylline to caffeine and vice versa may affect the\nindividual methylxanthine relationships, the total methylxanthine equatio<\/jats:p>","DOI":"10.1159\/000457387","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:07:41Z","timestamp":1502471261000},"page":"18-27","source":"Crossref","is-referenced-by-count":7,"title":["Cross Validation of Serum to Saliva Relationships of\nCaffeine, Theophylline and Total Methylxanthines in\nNeonates"],"prefix":"10.1159","author":[{"given":"Narinder","family":"Khanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu M.","family":"Somani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Meneke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:00Z","timestamp":1776846840000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457387","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}